ReviR Therapeutics
ReviR Therapeutics develops medicines that target disease-linked RNA to treat cancer, rare genetic disorders, and infectious diseases. The company combines genomics, functional genomics, and an AI/machine learning–driven computational platform to discover and design RNA-targeting therapeutics and identify disease-relevant RNA motifs. Its technology expands the druggable space beyond proteins by targeting RNA structures and life-cycle mechanisms previously considered undruggable. ReviR operates as an R&D-focused biotechnology company advancing preclinical discovery and translational programs.
ReviR Therapeutics
ReviR Therapeutics develops medicines that target disease-linked RNA to treat cancer, rare genetic disorders, and infectious diseases. The company combines genomics, functional genomics, and an AI/machine learning–driven computational platform to discover and design RNA-targeting therapeutics and identify disease-relevant RNA motifs. Its technology expands the druggable space beyond proteins by targeting RNA structures and life-cycle mechanisms previously considered undruggable. ReviR operates as an R&D-focused biotechnology company advancing preclinical discovery and translational programs.
TL;DR
Founded: 2021
Focus: RNA-targeting therapeutics for cancer, rare genetic disorders, and infectious diseases
Platform: AI/ML-driven RNA discovery and design (VoyageR) plus splice-modulation capabilities (SpliceR)
Recent funding: Series A $30,000,000 (2024-07-26); latest Grant round dated 2025-01-30
Founders / leadership: Peng Yue (Co‑founder & CEO) and Yang Li
Company Overview
Problem Domain
Developing therapeutics that target disease-linked RNA to treat cancer, rare genetic disorders, and infectious diseases.
Founded
2021
Industry
Biotechnology
Tech Stack
Funding Track Record
30,000,000 USD
Series A announced/closed Jul 26, 2024; participating investors include Lapam Capital, 5Y Capital, CDH Investments, XtalPi, Yael Capital Management Limited, and CMT Research Foundation (as listed in funding details).
Latest funding round listed as a Grant dated Jan 30, 2025; amount not specified in the provided evidence; recent investors associated with the company include the California Institute for Regenerative Medicine (CIRM) and Lapam Capital.
Investor Signal
“Syndicate includes venture investors (e.g., Lapam Capital, 5Y Capital, CDH Investments, XtalPi, Yael Capital) and a regional/public funder (California Institute for Regenerative Medicine); Series A led by Lapam Capital.”